Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
$609K Buy
5,015
+117
+2% +$15.6K ﹤0.01% 389
2023
Q1
$752K Sell
4,898
-423
-8% -$69.8K ﹤0.01% 354
2022
Q4
$956K Buy
5,321
+1,902
+56% +$311K ﹤0.01% 314
2022
Q3
$404K Sell
3,419
-493
-13% -$74.8K ﹤0.01% 425
2022
Q2
$559K Buy
+3,912
New +$559K ﹤0.01% 403

Other funds holding MRNA

TIAA FSB's MRNA Position: Q2 2023 in Review

TIAA FSB increased its Moderna (MRNA) stake by 2.4% in Q2 2023, buying an estimated $15.6K and bringing the position to 5,015 shares worth $609K. The position accounts for ﹤0.01% of the portfolio, ranked #389.

TIAA FSB first reported a position in MRNA in Q2 2022 and has held it in 5 quarters since. The position peaked at $956K in Q4 2022. 965 funds tracked by Wall St. Rank hold MRNA as of Q2 2023.

  • TIAA FSB held 5,015 shares of Moderna worth $609K as of Q2 2023.
  • TIAA FSB bought 117 Moderna shares in Q2 2023, an estimated $15.6K.
  • Moderna made up ﹤0.01% of TIAA FSB's portfolio in Q2 2023, its #389 holding.
  • TIAA FSB first reported a position in Moderna in Q2 2022 and has held it in 5 quarters since.
  • TIAA FSB's Moderna position peaked at $956K in Q4 2022.
  • 965 funds tracked by Wall St. Rank held Moderna as of Q2 2023.

Based on TIAA FSB's 13F filing for Q2 2023, filed 31 Jul 2023.